NCT02517502View on ClinicalTrials.gov

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

May 3, 2019

Conditions
Cognitive Dysfunction
Interventions
DRUG

DHA

4 capsules of 400 mg DHA daily

DRUG

Placebo

Matched, blinded placebo

Trial Locations (2)

62526

Decatur Memorial Hospital, Decatur

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

DSM Nutritional Products, Inc.

INDUSTRY

lead

Carol Fabian, MD

OTHER

NCT02517502 - Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy | Biotech Hunter | Biotech Hunter